H&H International Holdings (01112) rose more than 3% intraday. As of press time, the stock was up 2.61% at HK$20.42, with turnover of HK$37.0026 million.

Pacific Securities noted that rising health awareness among younger demographics is driving upward momentum in health consumption, and the health supplement industry is expected to see sustained catalysts.

Public information shows that Swisse, under H&H International Holdings, positions itself around "nature plus scientific nutrition" and has built a full life-cycle product matrix, becoming the number one health supplement brand in both mainland China and Australia.

Guotai Haitong Securities released a research report initiating coverage of H&H International Holdings with an "Accumulate" rating. It estimates the company's EPS for 2026-2028 at RMB 1.63/1.88/2.04. Considering that the company is gradually reducing debt and the proportion of its health supplement business continues to rise, under the resonance of an upward earnings cycle and improving debt cycle, the company is expected to undergo a revaluation. The report initiates coverage with an 18x PE for 2026, corresponding to a target price of HK$34.12.